THOROFARE, N.J., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), (the "Company" or "ABI"), a leading designer and manufacturer of rapid diagnostic screening and testing products, announced a contract valued at $864,000 for sales of its innovative Tri-Cholesterol "Check" tests in Australia, Singapore, the United Arab Emirates and Oman. The Company's products are being distributed in such regions by 36 Strategies General Trading LLC ("36S"), a Dubai-based procurement solutions company. Target customers in Australia, Singapore, the United Arab Emirates and Oman include military forces, medical associations, universities and large companies operating in the resources sector.
The Company's Tri-Cholesterol "Check" is a revolutionary finger-stick blood sample technology and the only combined rapid test which provides an estimate of both Total and High Density Lipoprotein ("HDL") cholesterol levels; thereby providing an estimate of the subject's Low Density Lipoprotein ("LDL") levels.
ABI's Tri-Cholesterol "Check" test carries a U.S. Food and Drug Administration ("FDA") Over-the-Counter approval; three CE marks for the European Economic Area; and a Health Canada approval.
Raymond F. Akers Jr., Ph.D, Executive Chairman of Akers Biosciences, stated, "This order gives us confidence that this test could become a very important and widely used test worldwide. There are an estimated 200 million people worldwide who have abnormal cholesterol levels. Our self-administered point-of-care test for cholesterol is easy-to-use, low cost, and revolutionary in point-of-care diagnostics. We are very pleased with the sales results we have achieved in these regions in a very short time through our distribution partner in the Middle East."
Revenue related to this order for Tri-Cholesterol "Check" tests (a Rapid Enzymatic Assay product) was recognized in the accounts for the six months ended June 30, 2014.
ABOUT AKERS BIOSCIENCES, INC.
Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be found on our website at www.akersbiosciences.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.
CONTACT: For more information: Raymond F. Akers, Jr. PhD Executive Chairman of the Board Akers Biosciences, Inc. Tel: +1 856 848 8698 Brendan Hopkins RedChip Companies, Inc. (US Investor Relations) Tel: +1 407 644 4256 x134 finnCap (UK Nominated Adviser and Broker) Geoff Nash / Scott Mathieson (Corporate Finance) Steve Norcross (Broking) Tel: +44 (0)20 7220 0500 Ben Simons / Alexandra Roper Vigo Communications (UK Investor Relations) Tel: +44 (0)20 7016 9570 firstname.lastname@example.org
Source:Akers Biosciences, Inc.